These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 33717088)

  • 1. Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.
    Renrick AN; Thounaojam MC; de Aquino MTP; Chaudhuri E; Pandhare J; Dash C; Shanker A
    Front Immunol; 2021; 12():607044. PubMed ID: 33717088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.
    Pellom ST; Dudimah DF; Thounaojam MC; Uzhachenko RV; Singhal A; Richmond A; Shanker A
    Oncotarget; 2017 Jan; 8(5):8604-8621. PubMed ID: 28052005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
    Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
    Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity.
    Huffaker TB; Hu R; Runtsch MC; Bake E; Chen X; Zhao J; Round JL; Baltimore D; O'Connell RM
    Cell Rep; 2012 Dec; 2(6):1697-709. PubMed ID: 23200854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopharmacological effect of β-d-mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miR-155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients.
    Mortazavi-Jahromi SS; Aslani M; Omidian S; Ahmadzadeh A; Rezaieyazdi Z; Mirshafiey A
    Drug Dev Res; 2020 May; 81(3):295-304. PubMed ID: 31675124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines.
    Ji Y; Wrzesinski C; Yu Z; Hu J; Gautam S; Hawk NV; Telford WG; Palmer DC; Franco Z; Sukumar M; Roychoudhuri R; Clever D; Klebanoff CA; Surh CD; Waldmann TA; Restifo NP; Gattinoni L
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):476-81. PubMed ID: 25548153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8
    Ji Y; Fioravanti J; Zhu W; Wang H; Wu T; Hu J; Lacey NE; Gautam S; Le Gall JB; Yang X; Hocker JD; Escobar TM; He S; Dell'Orso S; Hawk NV; Kapoor V; Telford WG; Di Croce L; Muljo SA; Zhang Y; Sartorelli V; Gattinoni L
    Nat Commun; 2019 May; 10(1):2157. PubMed ID: 31089138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model.
    Huang Z; Peng S; Knoff J; Lee SY; Yang B; Wu TC; Hung CF
    J Biomed Sci; 2015 Jan; 22(1):7. PubMed ID: 25591912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-155 influences cell-mediated immunity in Balb/c mice treated with aflatoxin M
    Shirani K; Riahi Zanjani B; Mehri S; Razavi-Azarkhiavi K; Badiee A; Hayes AW; Giesy JP; Karimi G
    Drug Chem Toxicol; 2021 Jan; 44(1):39-46. PubMed ID: 30739504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
    Cacan E; Spring AM; Kumari A; Greer SF; Garnett-Benson C
    Int J Mol Sci; 2015 Dec; 16(12):30405-21. PubMed ID: 26703577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-149-3p reverses CD8
    Zhang M; Gao D; Shi Y; Wang Y; Joshi R; Yu Q; Liu D; Alotaibi F; Zhang Y; Wang H; Li Q; Zhang ZX; Koropatnick J; Min W
    Open Biol; 2019 Oct; 9(10):190061. PubMed ID: 31594465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155.
    Guo J; Liao M; Wang J
    Cell Commun Signal; 2021 Sep; 19(1):90. PubMed ID: 34479599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins.
    Zimmerer JM; Lesinski GB; Kondadasula SV; Karpa VI; Lehman A; Raychaudhury A; Becknell B; Carson WE
    J Immunol; 2007 Apr; 178(8):4832-45. PubMed ID: 17404264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activin-A impedes the establishment of CD4
    Morianos I; Tsitsopoulou A; Potaris K; Valakos D; Fari O; Vatsellas G; Bostantzoglou C; Photiades A; Gaga M; Xanthou G; Semitekolou M
    J Exp Clin Cancer Res; 2021 Sep; 40(1):295. PubMed ID: 34548096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral Circulating Exosome-Mediated Delivery of miR-155 as a Novel Mechanism for Acute Lung Inflammation.
    Jiang K; Yang J; Guo S; Zhao G; Wu H; Deng G
    Mol Ther; 2019 Oct; 27(10):1758-1771. PubMed ID: 31405809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-155 Upregulation in Dendritic Cells Is Sufficient To Break Tolerance In Vivo by Negatively Regulating SHIP1.
    Lind EF; Millar DG; Dissanayake D; Savage JC; Grimshaw NK; Kerr WG; Ohashi PS
    J Immunol; 2015 Nov; 195(10):4632-40. PubMed ID: 26447227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.
    Martinez-Usatorre A; Sempere LF; Carmona SJ; Carretero-Iglesia L; Monnot G; Speiser DE; Rufer N; Donda A; Zehn D; Jandus C; Romero P
    Cancer Immunol Res; 2019 Jun; 7(6):1013-1024. PubMed ID: 31043416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.